|
Clinicopathological data of the patients and their relationships with ERBB2 expression |
|||||||
| Characteristic |
n |
(Percentage) |
ERBB2 expression (percentage) |
P value |
|||
| (0/1+/2+) |
(3+) |
||||||
|
|
|||||||
| Number of patients |
55 |
(100) |
40 |
(73) |
15 |
(27) |
|
| Tumor size |
NS |
||||||
| T1 |
20 |
(36) |
16 |
(80) |
4 |
(20) |
|
| T2 |
29 |
(53) |
20 |
(69) |
9 |
(31) |
|
| T3 |
6 |
(11) |
4 |
(67) |
2 |
(33) |
|
| Lymph node status |
NS |
||||||
| Negative |
33 |
(60) |
24 |
(73) |
9 |
(27) |
|
| Positive |
22 |
(40) |
16 |
(73) |
6 |
(27) |
|
| Grade |
|||||||
| Not determined |
3 |
(5) |
/ |
||||
| I |
12 |
(22) |
29 |
(83) |
6 |
(17) |
0.060 |
| II |
23 |
(42) |
|||||
| III |
17 |
(31) |
10 |
(59) |
7 |
(41) |
|
| Histological type |
NS |
||||||
| Ductal |
40 |
(73) |
28 |
(70) |
12 |
(30) |
|
| Lobular |
7 |
(13) |
5 |
(71) |
2 |
(29) |
|
| Other |
8 |
(14) |
7 |
(87) |
1 |
(13) |
|
| ER status |
0.035 |
||||||
| Positive |
42 |
(76) |
34 |
(81) |
8 |
(19) |
|
| Negative |
13 |
(24) |
6 |
(46) |
7 |
(54) |
|
| PR status |
0.022 |
||||||
| Positive |
32 |
(58) |
27 |
(84) |
5 |
(16) |
|
| Negative |
23 |
(42) |
13 |
(57) |
10 |
(43) |
|
| Menopausal status |
NS |
||||||
| Premenopausal |
9 |
(16) |
8 |
(89) |
1 |
(11) |
|
| Postmenopausal |
46 |
(84) |
32 |
(70) |
14 |
(30) |
|
| Ki67 |
0.018 |
||||||
| Low |
29 |
(53) |
25 |
(86) |
4 |
(14) |
|
| High |
26 |
(47) |
15 |
(58) |
11 |
(42) |
|
| p53 |
0.052 |
||||||
| Low |
46 |
(84) |
36 |
(78) |
10 |
(22) |
|
| High |
9 |
(16) |
4 |
(44) |
5 |
(56) |
|
|
ER, estrogen receptor; grade, Elston-Ellis modification of Bloom grade; NS, not significant; PR, progesterone receptor. | |||||||
Allouche et al. Breast Cancer Research 2008 10:R9 doi:10.1186/bcr1851 |
|||||||